Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients

▴ Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients
It will be the first clinical trial in China for UME treatment, and also the first one in China to adopt suprachoroidal space (SCS) injection, which is expected to provide a new treatment option for Chinese patients with UME.

Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of Uveitic Macular Edema (UME) by China National Medical Products Administration (NMPA). It will be the first clinical trial in China for UME treatment, and also the first one in China to adopt suprachoroidal space (SCS) injection, which is expected to provide a new treatment option for Chinese patients with UME.

This is also the first IND approval for Arctic Vision. "As an emerging Ophthalmology company, we are very excited. It is a major milestone," said Eddy (Hoi Ti) Wu, Ph.D., Founder, and CEO of Arctic Vision. "It took only 9 months for us to get the IND approval after obtaining the exclusive license of TA suprachoroidal injectable suspension, fully demonstrating the 'China speed'. We will work with ophthalmic experts closely to advance this clinical trial. We will strive to get the new drug approval in China as soon as possible to bring the revolutionary solution to patients with UME, to meet urgent clinical needs, and aim to lead the ophthalmology market in China."

The main objective of the current Phase III clinical trial is to evaluate the efficacy and safety of ARVN001 in patients with macular edema secondary to non-infectious uveitis. Results from preclinical studies showed that ARVN001 exhibits good efficacy in multiple animal models, and the unique pharmacokinetic characteristics led to improved efficacy and fewer adverse reactions. The completed US pivotal Phase 3 clinical trial also demonstrated significant improvement in vision for patients UME.

It is estimated that there are 3-5 million patients suffering from uveitis in China, representing one of the leading causes of visual impairment among the working-age population. Macular edema (ME) is one of the most common structural complications of Uveitis, and also the most frequent cause of both reversible and long-term visual loss among the patients. "The management of UME is one of the major challenges for ophthalmologists in the current clinical practice," said Professor Yang Peizeng, Vice-President of the Chinese Ophthalmological Society, Director of Chongqing Municipal Key Laboratory of Ophthalmology, and Director of the Ophthalmology Department of the First Affiliated Hospital of Chongqing Medical University. "We are excited that Arctic Vision brings the suprachoroidal space injection technology to China so that we could have a new treatment option for UME. I'm looking forward to the regulatory approval of the product in China as soon as possible so that it can help restore vision for millions of patients."

In March 2020, Arctic Vision obtained an exclusive license for the development and commercialization of ARVN001 (TA suprachoroidal injectable suspension developed by Clearside Biomedical, known as XIPERE™ in the United States) in Greater China and South Korea. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye. ARVN001 has been showing to effectively and safely improve the vision and reduce macular edema of patients with UME in the US Pivotal Phase III trial and has the potential to provide new options for other underserved retina-choroid diseases such as Diabetic macular edema (DME) and retinal vein occlusion (RVO).

About Uveitic Macular Edema (UME)

Uveitis is a set of ocular inflammatory conditions and one of the major causes of visual morbidity, it predominantly affects the younger population, and the consequent economic blindness imposes a greater burden on society and healthcare. Macular edema (ME) is a common complication in patients with uveitis, which is characterized by a build-up of fluid in the macula, the area of the retina responsible for sharp, straight-ahead vision. UME is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location—anterior, intermediate, posterior, or panuveitis.

About Suprachoroidal Space (SCS) Injection Platform

Injection of pharmacotherapy into the suprachoroidal space, between the sclera and choroid, is a novel delivery technique developed with the rationale of providing higher drug concentrations to posterior ocular structures compared with other intraocular and periocular injection procedures. Suprachoroidal (SC) injection with our proprietary SCS Microinjector® could enhance the delivery of therapies for a variety of ophthalmic conditions in which a precise anatomic drug application may yield safety, efficacy, and durability benefits over current therapies.

Targeted: Suprachoroidal injection enables the circumferential dispersion of medicine within the suprachoroidal space to the back of the eye, and quickly reaches a high concentration in the choroid and retina.

Safety: this ocular distribution pattern facilitates compartmentalization within the SCS, minimizing exposure to the anterior chamber and the vitreous, with the potential for safety benefits. It may limit corticosteroid exposure to the anterior chamber, iris, ciliary body, and lens, offering the potential to decrease adverse events (AEs) such as cataracts, intraocular pressure (IOP) elevation, and exacerbation of glaucoma that commonly arise from intravitreal and periocular corticosteroids.

Durability: sustained duration and favorable pharmacokinetics have been observed, with the potential to reduce treatment burden.

The proprietary SCS Microinjector® is inherently flexible and intended to work with established medications, new formulations of medicines, as well as future innovations such as gene therapy.

About Arctic Vision

Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. 

Tags : #China #ArticVision #Shanghai #ophthalmologycompany #InvestigationalNewDrug #PhaseIIItrial #ARVN001 #Treatment #UveiticMacularEdema #suprachoroidalspace #ophthalmology #PatientSafety #ChinaNewsUpdates

Related Stories

Loading Please wait...


Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023